VTCN1 and cancer: We demonstrated that the anti-cancer efficacy of 2B7 is mediated by the inhibition of the IGF1/IGF1Rβ and OPN/CD44 signaling, both central to cancer stem cell regulation, and by suppressing immune evasion via downregulation of PD-L1 and B7-H4.